Literature DB >> 11517419

Designs for clinical trials to test the efficacy of therapeutics in progressive multifocal leukoencephalopathy.

C T Yiannoutsos1, A De Luca.   

Abstract

The design of a comparative treatment trial to evaluate the efficacy of therapeutics for progressive multifocal leukoencephalopathy (PML) is outlined. We propose a large simple randomized trial with patient survival as its primary endpoint, completed in a short period of time and involving a cohort with as few enrollment restrictions as possible. We use stratification as the counterweight to the lack of exclusion criteria and suggest that proper stratification will attenuate differences inherent in a heterogeneous subject cohort. Estimation of power, sample size, and study duration, implementation of interim analyses, toxicity management, and validation of secondary clinical measures are also addressed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11517419     DOI: 10.1080/13550280152537265

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  26 in total

1.  Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV.

Authors:  J M Tassie; J Gasnault; M Bentata; J Deloumeaux; F Boué; E Billaud; D Costagliola
Journal:  AIDS       Date:  1999-10-01       Impact factor: 4.177

2.  Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy.

Authors:  A M Brambilla; A Castagna; R Novati; P Cinque; M R Terreni; M C Moioli; A Lazzarin
Journal:  J Neurol       Date:  1999-08       Impact factor: 4.849

3.  Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy.

Authors:  T Weber; C Trebst; S Frye; P Cinque; L Vago; C J Sindic; W J Schulz-Schaeffer; H A Kretzschmar; W Enzensberger; G Hunsmann; W Lüke
Journal:  J Infect Dis       Date:  1997-07       Impact factor: 5.226

4.  JC virus-specific cytotoxic T lymphocytes in individuals with progressive multifocal leukoencephalopathy.

Authors:  I J Koralnik; R A Du Pasquier; N L Letvin
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response.

Authors:  B Giudici; B Vaz; S Bossolasco; S Casari; A M Brambilla; W Lüke; A Lazzarin; T Weber; P Cinque
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

6.  Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy.

Authors:  L Chang; T Ernst; C Tornatore; H Aronow; R Melchor; I Walot; E Singer; M Cornford
Journal:  Neurology       Date:  1997-04       Impact factor: 9.910

7.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

8.  Cidofovir added to HAART improves virological and clinical outcome in AIDS-associated progressive multifocal leukoencephalopathy.

Authors:  A De Luca; M L Giancola; A Ammassari; S Grisetti; A Cingolani; M G Paglia; A Govoni; R Murri; L Testa; A D Monforte; A Antinori
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

9.  Progressive multifocal leukoencephalopathy in patients with HIV infection.

Authors:  J R Berger; L Pall; D Lanska; M Whiteman
Journal:  J Neurovirol       Date:  1998-02       Impact factor: 2.643

10.  Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy.

Authors:  J R Berger; L Mucke
Journal:  Neurology       Date:  1988-07       Impact factor: 9.910

View more
  1 in total

1.  Topotecan in the treatment of acquired immunodeficiency syndrome-related progressive multifocal leukoencephalopathy.

Authors:  W Royal; B Dupont; D McGuire; L Chang; K Goodkin; T Ernst; M J Post; D Fish; G Pailloux; H Poncelet; M Concha; L Apuzzo; E Singer
Journal:  J Neurovirol       Date:  2003-06       Impact factor: 2.643

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.